On the last page in the section "About Syntara" it says that SNT-4728 is being "studied" in collaboration with Parkinson's UK. Although the word "studied" is deployed I had understood that a clinical trial in this indication is underway. Is this correct?
It also says regarding SNT-5505 that protocols for another two phase 1c/2 studies with SNT-5505 in patients with a blood cancer called myelodysplastic syndrome are in development and expected to commence recruitment by H1 2025. This suggests that two new clinical trials using SNT-5505 will commence this half year. Is this new news? Is this interpretation correct?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
6.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $97.64M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| SNT (ASX) Chart |
Day chart unavailable